18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas

Annals of Oncology

Volumn 11, Issue SUPPL. 1, 2000, Pages

  Mikhaeel, N G ^a   Timothy, A R ^a   Hain, S F ^a   O'Doherty, M J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Lymphoma; PET; Remission assessment; Residual masses

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE; VINBLASTINE; VINCRISTINE;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033996693     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_1.S147     Document Type: Conference Paper

References (18)

1. Orlandi E, Lazzarino M, Brusamolino E et al. Residual mediastinal widenning following therapy in Hodgkin's disease. Hematol Oncol 1990; 8: 125-31.
2. Surbone A, Longo DL, De Vita VT Jr et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management. J Clin Oncol 1988; 6: 1832-7.
3. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931-3.
4. North LB, Fuller LM. Sullivan-Halley JA et al. Regression of mediastinal Hodgkin disease after therapy: Evaluation of time interval. Radiology 1987; 164: 599-602.
5. Lewis E, Bernardino ME, Salvador PG et al. Post-therapy CT-detected mass in lymphoma patients: Is it viable tissue? J Comp Ass Tom 1982; 6: 792-5.
6. Djulbegovic B, Hendler FJ, Hamm J et al. Residual mediastinal mass after treatment of Hodgkin's disease: A decision analysis. Med Hypoth 1992; 38: 166-75.
7. Brisse H, Pacquement H, Burdairon E et al. Outcome of residual mediastinal masses of thoracic lymphomas in children: Impact on management and radiological follow-up strategy. Pediatr Radiol 1998; 28: 444-50.
8. Glenn LD, Kumar PP. The residual mediastinal mass following radiation therapy for Hodgkin's disease. Am J Clin Oncol 1991; 14: 16-24.
9. Wittich GR, Nowels KW, Korn RL et al. Coaxial transthoracic fine-needle biopsy in patients with a history of malignant lymphoma. Radiology 1992; 183: 175-8.
10. Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995; 25: 60-71.
11. Setoain FJ, Pons F, Herranz R et al. 67-Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphomas. Nucl Med Commun 1997; 18: 405-11.
12. Mikhaeel NG, Ahern V, Barrington S et al. Post-treatment remission assessment in lymphoma using FDG-PET scanning. Br J Cancer 1997; 76 (Suppl 1): 32.
13. Cremerius U, Fabry U, Neuerurg J et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19: 1055-63.
14. Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy for advanced Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide vs. MOPP. Cancer 1975; 36: 252-9.
15. McKelvey EM, Gottlieb JA, Wilson HE. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-93.
16. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-6.
17. International Commission on Radiological Protection (ICRP). Pergamon Press: Annals of the ICRP 53. 1987; 18: 1-4.
18. Shrimpton PC, Jones DG, Hillier MC et al. Survey of CT Practice in the UK. Part 2: Dosimetric Aspects. London: HSMO 1991; NRBP-R249.